Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
LABORATORIO FARMACEUTICO ERFO S.P.A. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 0.934 EUR | -0.21% | -1.48% | -53.99% | |
| Nov. 13 | Laboratorio Farmaceutico Erfo has purchased 15,000 of its own shares | AN |
| Nov. 10 | Futures down after Powell speech. | AN |
| Sales 2023 * | 6.3M 6.8M | Sales 2024 * | 7.3M 7.88M | Capitalization | 8.41M 9.08M |
|---|---|---|---|---|---|
| Net income 2023 * | - 0 | Net income 2024 * | 1M 1.08M | EV / Sales 2023 * | 1,08x |
| Net cash position 2023 * | 1.6M 1.73M | Net cash position 2024 * | 2.9M 3.13M | EV / Sales 2024 * | 0,75x |
| P/E ratio 2023 * | 10,4x | P/E ratio 2024 * | 8,49x | Employees | 29 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 22.6% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.21% | ||
| 1 week | -1.48% | ||
| Current month | -0.64% | ||
| 1 month | -3.71% | ||
| 3 months | -20.17% | ||
| 6 months | -18.78% | ||
| Current year | -53.99% |
1 week
0.88
0.96
1 month
0.880.98
Current year
0.882.02
1 year
0.882.03
3 years
0.883.30
5 years
0.883.30
10 years
0.883.30
| Managers | Title | Age | Since |
|---|---|---|---|
Flavio Corpina
CEO | Chief Executive Officer | 44 | 2016 |
Alessandro Cutè
CEO | Chief Executive Officer | 53 | 2012 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alessandro Cutè
CEO | Chief Executive Officer | 53 | 2012 |
Flavio Corpina
CEO | Chief Executive Officer | 44 | 2016 |
Fabio Giuffre
BRD | Director/Board Member | 42 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-05 | 0.934 | -0.21% | 5 000 |
| 23-12-04 | 0.936 | +0.65% | 9,000 |
| 23-12-01 | 0.93 | -1.06% | 15,000 |
| 23-11-30 | 0.94 | -2.08% | 15,000 |
| 23-11-29 | 0.96 | +3.67% | 16,000 |
Real-time Borsa Italiana, December 05, 2023 at 11:44 am EST
More quotes
Laboratorio Farmaceutico Erfo SpA is an Italy-based pharmaceutical company primarily engaged in the nutraceutical sector. The Company specializes in the production of nutritional supplements, that thanks to research and development carried out internally and in collaboration with the University Campus Bio-Medico of Rome and the University of Messina provides products with a scientific value in different therapeutic areas. The Company operates globally.
Sector
Pharmaceuticals
Trading Rating :
Investor Rating :
ESG Refinitiv :
-
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.934EUR
Average target price
2EUR
Spread / Average Target
+114.13%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -53.99% | 9 M $ | |
| +60.77% | 527 B $ | |
| +46.50% | 448 B $ | |
| -10.25% | 382 B $ | |
| -4.25% | 266 B $ | |
| -10.54% | 255 B $ | |
| -13.61% | 227 B $ | |
| +1.76% | 203 B $ | |
| -9.57% | 201 B $ | |
| -43.23% | 165 B $ |
